![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SOLVAY JOINS ABBOTT/ASTRAZENECA DEAL TO DEVELOP FENOFIBRATE IN THE U.S.
SOLVAY JOINS ABBOTT/ASTRAZENECA DEAL TO DEVELOP FENOFIBRATE IN THE U.S.
July 13, 2006
Pharmaceutical groups AstraZeneca and Abbott announced that they will jointly develop and commercialize in the United States a fixed-dose combination product containing two lipid-regulating agents. This new combination product will be promoted in the U.S. by both companies, with a target 2009 for regulatory submission. The new product will combine Crestor (AstraZeneca's rosuvastatin) with either TriCor (Solvay's fenofibrate, licensed to Abbott for the U.S.) or a next-generation fenofibrate developed by Abbott and Solvay as a new lipid-regulating agent.
In addition to this new fixed-dose combination in the U.S., Solvay has several other products in development. The next one out of this string of projects is expected to be Synordia (previously known as Dualthys), a fixed-dose combination of an oral antidiabetic (metformin) and fenofibrate for Type II diabetic patients, due to be submitted for European Union registration this summer.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct